Strengthen your value story with HEOR


HEOR is a field of research that provides real-world data and insights to demonstrate the clinical and economic value of pharmaceutical products and medical devices.
Unlike clinical trials, which demonstrate safety and efficacy, our research helps demonstrate therapeutic value and impact.
Recent news and publications from Optum HEOR experts
- Recent publication: Real-world primary nonadherence to antiobesity medications
- Recent publication: Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C
- Recent presentation: Patterns of Colorectal Cancer (CRC) Screening Rates among the Average Risk U.S. Population
Meet with us at upcoming events
Answer your toughest research questions
Consider the following questions as you address health outcomes in the life sciences space.
Disease burden
How are patients impacted?
Unmet need
What gaps in care can your product help address?
Treatment patterns
How are your medications used to treat patients?
Total cost of care
Are there medical cost offsets associated with a treatment option?
Adherence
Do patients take their medication correctly?
Comparative effectiveness
How do the outcomes of patients using the competitor’s product compare?
Video
Providing actionable HEOR data to prove cost-effectiveness
See how we worked with a medical device company to prove their device was more cost-effective than the current standard of care.

- captions off, selected
- English for the hard of hearing Captions
This is a modal window.
^B00:00:01
The curious case of the costly complication. A medical device company cleared a major hurdle with FDA approval for their new product, but they hit a snag when commercial payers refused to provide a medical coverage policy for the device. When this happens it can be difficult and costly for patients to access treatment even if its the best available. In order to be covered, the device company needed to prove their device was more cost effective than the current standard of care. But how? Enter Optum®, a leading health services and innovation company with years of proven experience helping clients find solutions to difficult problems. Optum had the keys to unlock the answers with a massive amount of de-identified, real-world patient data from claims and electronic health records and the technology and expertise to integrate, sort, and analyze that data.
^M00:01:08
Like all surgical procedures, the current standard of care comes with possible complications. After hearing the device company’s story, Optum began to dig deeper into the data and quantify the costs of those complications. If the newly approved device could avoid or minimize complications and associated costs, the device company would have the proof they needed to differentiate their solution. The first step was to compile a list of “complication codes”. This required close collaboration between the Optum Medical Director and the device company’s Medical Director, a practicing physician familiar with both the current standard of care and his company’s solution. Optum data identified patients who had undergone the surgical procedure during a seven-year period, and included the associated diagnosis and procedure codes.
M00:02:06
The Medical Directors were able to cross-reference the codes and determine which ones pointed to complications post-procedure. Armed with that knowledge, Optum zeroed in on the medical and pharmacy costs associated with the complications, looking at key variables, at 90 days, one year, and three years post-procedure. The Optum data provided other clues around; condition diagnosis, prescriptions for medications, and condition-related health care utilization. The company soon discovered exactly what they needed. Optum’s cost analysis gave them actionable data to drive discussions and impact decisions. Another case closed. Now on to the next one.
^E00:02:57
Leaders with deep domain expertise and industry knowledge
Our capabilities and experience span many therapeutic areas, including oncology, infectious disease and cardiovascular disease. Get to know our leaders.
Voice-to-Claim™ research: Explore patient and provider journeys
Investigate patient and physician attitudes about treatment and insights into how decisions are made.

Explore therapeutic areas
Our therapeutic focus supports the development of disease-specific capabilities and infrastructure.
Cardiovascular disease
Developing research to advance the treatment of CVD, including dysrhythmia, hypertension and heart failure
Central nervous system and behavioral health
Offering insights in Alzheimer’s, dementia, depression, and more
Diabetes and other endocrine diseases
Gaining insight on diabetes and other endocrine conditions
Infectious disease
Combining real-world data and extensive therapeutic expertise to showcase the value of ID therapies
Oncology and immunology
Offering expertise in solid tumors, hematologic malignancies and other inflammatory conditions
Respiratory disease
Supporting our clients in evidence generation for asthma, COPD and other respiratory disease products
Sell sheet
Explore our HEOR capabilities
Design and conduct studies to generate real-world evidence of the value of medications and medical devices.

Let us help you connect the dots
From data to insight to action, we catalyze innovation and commercial impact. Work with us on your HEOR needs.
Find our HEOR experts at upcoming events
Related content

Solve contract challenges for gene therapies
There are hurdles to overcome for value-based contracts to become widespread.

Novel data collection for a difficult-to-study condition

Sleep treatment across the ages
Combining real-world data and primary research helps us better understand insomnia.
Complementary solutions
Engage payers with value-based contracts
Assess the fit, develop metrics and track care outcomes over time.
Gain greater insights through clinicogenomics
Better understand diseases and drug development opportunities.
Generate evidence with real-world data
Derive evidence from the unmatched depth and scale of our data assets.